Serum ZFPL1 as a clinical biomarker for diagnosis, progression tracking, and treatment response in lung cancer
Serum ZFPL1 may serve as a novel serological biomarker for lung cancer diagnosis. Changes in serum ZFPL1 levels can effectively evaluate the efficacy of chemotherapy and surgical treatment, and serum ZFPL1 has potential predictive value for disease progression in lung cancer.
Authors
- Guanjie Lu
- Biwen Mo (ORCID: https://orcid.org/0000-0001-7726-3149)
- Shu‐wen W. Chen (ORCID: https://orcid.org/0000-0003-4205-4931)
- Jianhua Feng (ORCID: https://orcid.org/0000-0002-5849-407X)
- Haihui Yang (ORCID: https://orcid.org/0009-0001-7736-6188)
- Honglin Liu (ORCID: https://orcid.org/0000-0003-0910-2444)
- Yingxuan Chen (ORCID: https://orcid.org/0000-0002-1883-7736)
- Teng Yu (ORCID: https://orcid.org/0000-0001-7069-4480)
- Lili Xu (ORCID: https://orcid.org/0000-0002-6561-2329)
- Xiaoni Pang
Institutions
- Guilin Medical University (CN)
- Zhongshan City Second People's Hospital (CN)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1016/j.ctarc.2025.101052
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00